{"DataElement":{"publicId":"2856929","version":"1","preferredName":"Cancer and Leukemia Group B Patient Inclusion Clinical Trial Eligibility Criteria 90601 Type","preferredDefinition":"CALGB 90601 elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"C_PT_IN_CTE_90601_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2625931","version":"1","preferredName":"Cancer and Leukemia Group B Patient Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"CALGB_PT_INCL_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2625929","version":"1","preferredName":"Cancer and Leukemia Group B Patient","preferredDefinition":"The Cancer and Leukemia Group B (CALGB) is a national clinical research group - network of 29 university medical centers, over 185 community hospitals and more than almost 3000 physicians - sponsored by the NCI, with its Central Office headquartered at the University of Chicago, and its Statistical Center located at Duke University, founded in 1955 with a goal of bringing together clinical and laboratory research.:A person who requires medical care.","longName":"C25442:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cancer and Leukemia Group B","conceptCode":"C25442","definition":"A national clinical research group - network of 29 university medical centers, over 185 community hospitals and more than almost 3000 physicians - sponsored by the NCI, with its Central Office headquartered at the University of Chicago, and its Statistical Center located at Duke University, founded in 1955 with a goal of bringing together clinical and laboratory research.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DB1F788-C668-1ADE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-04-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-09","modifiedBy":"ONEDATA","dateModified":"2007-04-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2518229","version":"1","preferredName":"Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25532:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inclusion Criteria","conceptCode":"C25532","definition":"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08D4-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2DB30129-B326-1BB8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-04-09","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2856907","version":"1","preferredName":"90601 Inclusion Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility inclusion criteria for a Cancer and Leukemia Group B protocol 90601.","longName":"90601_INCL_CTEC_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Age >= 18 yrs","valueDescription":"Age >= 18 yrs","ValueMeaning":{"publicId":"2856908","version":"1","preferredName":"Age >= 18 yrs","longName":"2856908","preferredDefinition":"Age >= 18 yrs","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-E8B6-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-E8CF-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"ECOG Performance Status: 0-1","valueDescription":"ECOG Performance Status: 0-1","ValueMeaning":{"publicId":"2856909","version":"1","preferredName":"ECOG Performance Status: 0-1","longName":"2856909","preferredDefinition":"ECOG Performance Status: 0-1","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-E8D9-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-E8F2-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"No known hypersensitivity to Chinese hamster ovary cell products","valueDescription":"No known hypersensitivity to Chinese hamster ovary cell products","ValueMeaning":{"publicId":"2856910","version":"1","preferredName":"No known hypersensitivity to Chinese hamster ovary cell products","longName":"2856910","preferredDefinition":"No known hypersensitivity to Chinese hamster ovary cell products","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-E8FC-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-E915-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"Not pregnant or nursing","valueDescription":"Not pregnant or nursing","ValueMeaning":{"publicId":"2856911","version":"1","preferredName":"Not pregnant or nursing","longName":"2856911","preferredDefinition":"Not pregnant or nursing","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-E91F-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-E938-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"No clinically significant peripheral neuropathy (grade >= 2)","valueDescription":"No clinically significant peripheral neuropathy (grade >= 2)","ValueMeaning":{"publicId":"2856912","version":"1","preferredName":"No clinically significant peripheral neuropathy (grade >= 2)","longName":"2856912","preferredDefinition":"No clinically significant peripheral neuropathy (grade >= 2)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-E942-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-E95B-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"No serious or non-healing wound, ulcer or bone fracture","valueDescription":"No serious or non-healing wound, ulcer or bone fracture","ValueMeaning":{"publicId":"2856913","version":"1","preferredName":"No serious or non-healing wound, ulcer or bone fracture","longName":"2856913","preferredDefinition":"No serious or non-healing wound, ulcer or bone fracture","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-E965-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-E97E-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"No arterial thrombotic events within 6 months","valueDescription":"No arterial thrombotic events within 6 months","ValueMeaning":{"publicId":"2856914","version":"1","preferredName":"No arterial thrombotic events within 6 months","longName":"2856914","preferredDefinition":"No arterial thrombotic events within 6 months","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-E988-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-E9A1-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"No clinically significant peripheral arterial disease","valueDescription":"No clinically significant peripheral arterial disease","ValueMeaning":{"publicId":"2856915","version":"1","preferredName":"No clinically significant peripheral arterial disease","longName":"2856915","preferredDefinition":"No clinically significant peripheral arterial disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-E9AB-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-E9C4-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"No history of gastrointestinal perforation within 12 months of registration","valueDescription":"No history of gastrointestinal perforation within 12 months of registration","ValueMeaning":{"publicId":"2856916","version":"1","preferredName":"No history of gastrointestinal perforation within 12 months of registration","longName":"2856916","preferredDefinition":"No history of gastrointestinal perforation within 12 months of registration","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-E9CE-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-E9E7-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"No significant history of bleeding events within 6 months of registration","valueDescription":"No significant history of bleeding events within 6 months of registration","ValueMeaning":{"publicId":"2856917","version":"1","preferredName":"No significant history of bleeding events within 6 months of registration","longName":"2856917","preferredDefinition":"No significant history of bleeding events within 6 months of registration","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-E9F1-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EA0A-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"Patients on full-dose anticoagulants must be on a stable dose of warfarin and have an in-range INR or be on a stable dose of LMW heparin","valueDescription":"Patients on full-dose anticoagulants must be on a stable dose of warfarin and have an in-range INR or be on a stable dose of LMW heparin","ValueMeaning":{"publicId":"2856918","version":"1","preferredName":"Patients on full-dose anticoagulants must be on a stable dose of warfarin and have an in-range INR or be on a stable dose of LMW heparin","longName":"2856918","preferredDefinition":"Patients on full-dose anticoagulants must be on a stable dose of warfarin and have an in-range INR or be on a stable dose of LMW heparin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EA14-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EA2D-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"Patients with history of hypertension must be well controlled (< 150/90)","valueDescription":"Patients with history of hypertension must be well controlled (< 150/90)","ValueMeaning":{"publicId":"2856919","version":"1","preferredName":"Patients with history of hypertension must be well controlled (< 150/90)","longName":"2856919","preferredDefinition":"Patients with history of hypertension must be well controlled (< 150/90)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EA37-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EA50-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"No current congestive heart failure (NYHA Class II or higher)","valueDescription":"No current congestive heart failure (NYHA Class II or higher)","ValueMeaning":{"publicId":"2856920","version":"1","preferredName":"No current congestive heart failure (NYHA Class II or higher)","longName":"2856920","preferredDefinition":"No current congestive heart failure (NYHA Class II or higher)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EA5A-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EA73-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"No known brain metastases (brain imaging (MRI/CT) is not required)","valueDescription":"No known brain metastases (brain imaging (MRI/CT) is not required)","ValueMeaning":{"publicId":"2856921","version":"1","preferredName":"No known brain metastases (brain imaging (MRI/CT) is not required)","longName":"2856921","preferredDefinition":"No known brain metastases (brain imaging (MRI/CT) is not required)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EA7D-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EA96-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"Prior neoadjuvant / adjuvant chemotherapy is permissible","valueDescription":"Prior neoadjuvant / adjuvant chemotherapy is permissible","ValueMeaning":{"publicId":"2856922","version":"1","preferredName":"Prior neoadjuvant / adjuvant chemotherapy is permissible","longName":"2856922","preferredDefinition":"Prior neoadjuvant / adjuvant chemotherapy is permissible","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EAA0-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EAB9-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":">= 4 weeks from any intravesical therapy","valueDescription":">= 4 weeks from any intravesical therapy","ValueMeaning":{"publicId":"2856923","version":"1","preferredName":">= 4 weeks from any intravesical therapy","longName":"2856923","preferredDefinition":">= 4 weeks from any intravesical therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EAC3-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EADC-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":">= 4 weeks since any radiation therapy (including palliative) or major surgery and fully recovered","valueDescription":">= 4 weeks since any radiation therapy (including palliative) or major surgery and fully recovered","ValueMeaning":{"publicId":"2856924","version":"1","preferredName":">= 4 weeks since any radiation therapy (including palliative) or major surgery and fully recovered","longName":"2856924","preferredDefinition":">= 4 weeks since any radiation therapy (including palliative) or major surgery and fully recovered","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EAE6-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EAFF-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"No prior bevicizumab/ or other angiogenesis inhibitors","valueDescription":"No prior bevicizumab/ or other angiogenesis inhibitors","ValueMeaning":{"publicId":"2856925","version":"1","preferredName":"No prior bevicizumab/ or other angiogenesis inhibitors","longName":"2856925","preferredDefinition":"No prior bevicizumab/ or other angiogenesis inhibitors","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EB09-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EB22-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"No prior combination chemotherapy for metastatic disease","valueDescription":"No prior combination chemotherapy for metastatic disease","ValueMeaning":{"publicId":"2856926","version":"1","preferredName":"No prior combination chemotherapy for metastatic disease","longName":"2856926","preferredDefinition":"No prior combination chemotherapy for metastatic disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EB2C-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EB45-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"Histologically documented metastatic or unresectable transitional cell carcinoma of the urinary tract with","valueDescription":"Histologically documented metastatic or unresectable transitional cell carcinoma of the urinary tract with progressive metastatic disease or locally advanced disease","ValueMeaning":{"publicId":"2856927","version":"1","preferredName":"Histologically documented metastatic or unresectable transitional cell carcinoma of the urinary tract with progressive metastatic disease or locally advanced disease","longName":"2856927","preferredDefinition":"Histologically documented metastatic or unresectable transitional cell carcinoma of the urinary tract with\r\nprogressive metastatic disease or locally advanced disease","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EB4F-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EB68-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"Calculated Creatinine Clearance >= 60 mL/min","valueDescription":"Calculated Creatinine Clearance >= 60 mL/min","ValueMeaning":{"publicId":"2856930","version":"1","preferredName":"Calculated Creatinine Clearance >= 60 mL/min","longName":"2856930","preferredDefinition":"Calculated Creatinine Clearance >= 60 mL/min","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EB96-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EBAF-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"AST <= 2.0 x ULN","valueDescription":"AST <= 2.0 x ULN","ValueMeaning":{"publicId":"2856931","version":"1","preferredName":"AST <= 2.0 x ULN","longName":"2856931","preferredDefinition":"AST <= 2.0 x ULN","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EBB9-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EBD2-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"Bilirubin <= 1.25 x ULN","valueDescription":"Bilirubin <= 1.25 x ULN","ValueMeaning":{"publicId":"2856932","version":"1","preferredName":"Bilirubin <= 1.25 x ULN","longName":"2856932","preferredDefinition":"Bilirubin <= 1.25 x ULN","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EBDC-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EBF5-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"Platelet count >= 100,000/mm^3","valueDescription":"Platelet count >= 100,000/mm^3","ValueMeaning":{"publicId":"2680576","version":"1","preferredName":"Platelet count >= 100,000/mm^3","longName":"2680576","preferredDefinition":"Platelet count >= 100,000/mm^3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39E34F97-70CA-132A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-09-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EBFF-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"},{"value":"ANC >= 1500/mcl","valueDescription":"ANC >= 1500/mcl","ValueMeaning":{"publicId":"2856933","version":"1","preferredName":"ANC >= 1500/mcl","longName":"2856933","preferredDefinition":"ANC >= 1500/mcl","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-EC09-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"65FA6023-EC22-DD75-E040-BB89AD43216C","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ONEDATA","dateModified":"2009-03-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"65FA6023-E8A2-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ALAIS","dateModified":"2009-03-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811907","version":"1","longName":"Bladder","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811954","version":"1","longName":"Eligibility Criteria","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000462","version":"1","longName":"Muscle Invasive Blad","context":"CTEP"}]},{"publicId":"2008608","version":"1","longName":"Phase","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811890","version":"1","longName":"Phase III","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Patient eligibility","type":"Preferred Question Text","description":"Patient eligibility","url":null,"context":"CTEP"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"65FA6023-EB72-DD75-E040-BB89AD43216C","latestVersionIndicator":"Yes","beginDate":"2009-03-25","endDate":null,"createdBy":"ALAIS","dateCreated":"2009-03-25","modifiedBy":"ALAIS","dateModified":"2011-10-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}